Prognostic Value of the ¹³ C-Methacetin Breath Test in Adults with Acute Liver Failure and Non-acetaminophen Acute Liver Injury.

ABSTRACT:

Background and aims

The ¹³ C-methacetin breath test (MBT) is a noninvasive, quantitative hepatic metabolic function test. The aim of this prospective, multicenter study was to determine the utility of initial and serial ¹³ C-MBT in predicting 21-day outcomes in adults with acute liver failure (ALF) and non-acetaminophen acute liver injury (ALI).

Approach and results

The ¹³ C-MBT BreathID device (Exalenz Biosciences, Ltd.) provided the percent dose recovery (PDR) for a duration of 60 minutes after administration of ¹³ C-methacetin solution as the change in exhaled ¹³ CO₂ /¹² CO₂ compared with pre-ingestion ratio on study days 1, 2, 3, 5, and 7. Results were correlated with 21-day transplan

SUBMITTER: Fontana RJ 

PROVIDER: S-EPMC10683007 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature